Neratinib as adjuvant therapy in patients with HER2 positive breast cancer: expert opinion

Neratinib is a tyrosine kinase receptor inhibitor used in the extended adjuvant therapy of early-stage breast cancer. After adjuvant trastuzumab therapy, neratinib reduces the risk of recurrence and, if taken within 1 year from trastuzumab, significantly improves the invasive disease-free survival of patients with early-stage human epidermal growth factor receptor-2 positive (HER2+) breast cancer with no increased risk of long-term toxicity. Diarrhea, the most common adverse event associated with neratinib use, deters some clinicians from prescribing this drug. However, neratinib-related toxicity is predictable, short-lived, mostly limited to the first month of treatment and can be managed with dose-escalation and prophylactic strategies. Thus, close surveillance and prompt management, relying on supportive care and administration schedule modification, allows discontinuation of treatment to be avoided. Tweetable abstractNeratinib, administered within 1 year of trastuzumab, significantly improves disease-free survival in early-stage HER2+ breast cancer, with no increased risk of long-term toxicity. #neratinib #HER2+BC

Automated summary

Neratinib, used after adjuvant trastuzumab therapy, significantly improves disease-free survival in early-stage HER2+ breast cancer without increased risk of long-term toxicity. Diarrhea, the most common adverse event associated with neratinib, can be managed with dose-escalation and prophylactic strategies, allowing treatment continuation.